Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 100 of the 100 references it cites were found in a registry or an index.

The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research

Open access

Abstract

Treatment-resistant schizophrenia (TRS), the persistence of positive symptoms despite ≥2 trials of adequate dose and duration of antipsychotic medication with documented adherence, is a serious clinical problem with heterogeneous presentations. TRS can vary in its onset (at the first episode of psychosis or upon relapse), in its severity, and in the response to subsequent therapeutic interventions (i.e., clozapine, electroconvulsive therapy). The heterogeneity of TRS indicates that the underlying neurobiology of TRS may differ not only from treatment-responsive schizophrenia but also among patients with TRS. Several hypotheses have been proposed for the neurobiological mechanisms underlying TRS, including dopamine supersensitivity, hyperdopaminergic and normodopaminergic subtypes, glutamate dysregulation, inflammation and oxidative stress, and serotonin dysregulation. Research supporting these hypotheses is limited in part by variations in the criteria used to define TRS, as well as by the biological and clinical heterogeneity of TRS. Clinical trial designs for new treatments should be informed by this heterogeneity, and further clinical research is needed to more clearly understand the underlying neurobiology of TRS and to optimize treatment for patients with TRS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41537-019-0090-z

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Clinical path to confirmation of TRS. AP antipsychotic, ECT electroconvulsive therapy, TRS treatment-resistant schizophrenia. *If a trial of clozapine was not previously completed.
Fig. 1 Clinical path to confirmation of TRS. AP antipsychotic, ECT electroconvulsive therapy, TRS treatment-resistant schizophrenia. *If a trial of clozapine was not previously completed.CC BY · PubMed Central
Fig. 2 Dopaminergic pathways to treatment resistance. (a) Dopamine supersensitivity and (b) dopaminergic subtypes.
Fig. 2 Dopaminergic pathways to treatment resistance. (a) Dopamine supersensitivity and (b) dopaminergic subtypes.CC BY · PubMed Central
Fig. 3 Clinical research priorities for TRS. TRS treatment-resistant schizophrenia.
Fig. 3 Clinical research priorities for TRS. TRS treatment-resistant schizophrenia.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 100 references

Cited by

See all 381

Metadata

Authors
Potkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D.
Affiliations
  • University of California, Irvine (US)
  • Feinstein Institute for Medical Research (US)
  • NYU Langone Health (US)
  • Centre for Addiction and Mental Health (CA)
  • University of California, Los Angeles (US)
  • Columbia University Irving Medical Center (US)
  • King's College London (GB)
Corresponding author
Howes, Oliver D.
Venue
npj Schizophrenia
Published
2020-01-07
Volume
6
Issue
1
Pages
1-1
ISSN
2334-265X (ISSN-L)
OpenAlex
W2999966539
Cited by
359
References
100
Citations by year
2026: 42 · 2025: 62 · 2024: 65 · 2023: 61 · 2022: 55 · 2021: 53 · 2020: 21
FWCI
7.90
Type
journal article
Language
en
Open access
Licence
Locations
  • Schizophrenia (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion, cc-by)
Funders
Lundbeck
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
treatment-resistant schizophrenia, antipsychotic resistance, neurobiology, dopamine supersensitivity, glutamate dysregulation, inflammation, oxidative stress, serotonin dysregulation, clozapine, electroconvulsive therapy, first-episode psychosis, relapse, treatment effect heterogeneity

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. https://app.cochat.ai/papers/10.1038/s41537-019-0090-z
The paper
Potkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020). The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research. npj Schizophrenia. https://doi.org/10.1038/s41537-019-0090-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.